The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

Background: Recent trial data suggest that stratification of patients with heart failure with
preserved ejection fraction (HFpEF) according to left ventricular ejection fraction (LVEF) …

Patients with heart failure with preserved ejection fraction (HFpEF) universally complain of
exercise intolerance and dyspnoea as key clinical correlates. Cardiac as well as …

The heart is the most metabolically active organ in the human body, and cardiac metabolism
has been studied for decades. However, the bulk of studies have focused on animal models …

Obesity and its comorbidities, including type 2 diabetes mellitus, cardiovascular disease,
heart failure and non-alcoholic liver disease are a major health and economic burden with …

Cardiac metabolism is vital for heart function. Given that cardiac contraction requires a
continuous supply of ATP in large quantities, the role of fuel metabolism in the heart has …

Background: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a
paramount treatment for patients with heart failure (HF), irrespective of underlying reduced …

Aims Little data are available regarding prognostic implications of invasive exercise testing
in heart failure with preserved ejection fraction (HFpEF). The present study aimed to …

Aims Obesity is a risk factor for heart failure with preserved ejection fraction (HFpEF),
particularly in women, but the mechanisms remain unclear. The present study aimed to …